Cristina Csimma, PharmD, M.H.P.
Founder and Chief Executive Officer
Cydan Development, Inc
brings extensive drug development experience in the biopharmaceutical, venture capital and academic settings.
Prior to joining Cydan, Dr. Csimma worked in advisory roles with biopharmaceutical and venture capital firms, was Vice President, Drug Development at Virdante Pharmaceuticals Inc. and was a principal at Clarus Ventures LLC, a leading life sciences venture capital firm.
Previously, she held roles in CR&D and Translational Research at Wyeth Research and the Genetics Institute.
global drug development experience encompasses multiple therapeutic areas including neuromuscular disease, exploratory through registration clinical studies, and integration of biomarkers and novel technologies into clinical development.
Before joining the biopharmaceutical industry, she was a clinical pharmacist at the Dana-Farber Cancer Institute.
Dr. Csimma serves on the board of directors of Columbia Labs Inc., and is a member of the MDA Venture Philanthropy Scientific Development Advisory Committee; the external oversight board to the NIH NINDS NeuroNext (Network for Excellence in Neuroscience Clinical Trials); the TREAT-NMD Advisory Committee for Therapeutics (TACT) (former chair), the Department of Defense CDMRP Duchenne Muscular Dystrophy Research Program Integration Panel, and Northeastern University's Health Sciences Entrepreneurs program steering committee.
Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy, and a Master of Health Professions from Northeastern University.